HALDOL DECANOATE

Negara: Irlandia

Bahasa: Inggris

Sumber: HPRA (Health Products Regulatory Authority)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
23-06-2017
Karakteristik produk Karakteristik produk (SPC)
23-06-2017

Bahan aktif:

HALOPERIDOL DECANOATE

Tersedia dari:

Janssen-Cilag Ltd

Kode ATC:

N05AD01

INN (Nama Internasional):

HALOPERIDOL DECANOATE

Dosis:

100 Mg/Ml

Bentuk farmasi:

Solution for Injection

Jenis Resep:

Product subject to prescription which may not be renewed (A)

Area terapi:

haloperidol

Status otorisasi:

Marketed

Tanggal Otorisasi:

1989-08-03

Selebaran informasi

                                PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
HALDOL
® DECANOATE 50 MG/ML SOLUTION FOR INJECTION
HALDOL
® DECANOATE 100 MG/ML SOLUTION FOR INJECTION
haloperidol
Haldol is a registered trademark
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Haldol Decanoate is and what it is used for
2.
What you need to know before you are given Haldol Decanoate
3.
How to use Haldol Decanoate
4.
Possible side effects
5.
How to store Haldol Decanoate
6.
Contents of the pack and other information
1.
WHAT HALDOL DECANOATE IS AND WHAT IT IS USED FOR
The name of your medicine is Haldol Decanoate.
Haldol Decanoate contains the active substance haloperidol (as
haloperidol decanoate). This belongs
to a group of medicines called ‘antipsychotics’.
Haldol Decanoate is used in adults whose condition has previously been
treated with haloperidol
taken by mouth. It is used for illnesses affecting the way you think,
feel or behave. These include
mental health problems (such as schizophrenia). These illnesses may
make you:

Feel confused (delirium)

See, hear, feel or smell things that are not there (hallucinations)

Believe things that are not true (delusions)

Feel unusually suspicious (paranoia)

Feel very excited, agitated, enthusiastic, impulsive or hyperactive

Feel very aggressive, hostile or violent.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN HALDOL DECANOATE
DO NOT USE HALDOL DECANOATE IF:

You are allergic to haloperidol or any of the other ingredients of
this medicine (listed
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Haldol Decanoate 100mg/ml Solution for Injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 100 mg/ml ampoule contains 141.04 mg of haloperidol decanoate
equivalent to 100 mg of haloperidol.
Excipient: contains Benzyl Alcohol 15.0mg/ml and Sesame Oil 1.0ml.
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection.
Slightly amber, slightly viscous oily solution for intramuscular
injection.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
HALDOL Decanoate is indicated for the maintenance treatment of
schizophrenia and schizoaffective disorder in adult
patients currently stabilised with oral haloperidol (see section 5.1).
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Treatment initiation and dose titration must be carried out under
close clinical supervision.
Posology
The individual dose will depend on both the severity of the symptoms
and the current oral haloperidol dose. Patients
must always be maintained on the lowest effective dose.
As the initial dose of haloperidol decanoate is based on a multiple of
the daily oral haloperidol dose, specific guidance
on switching from other antipsychotics cannot be provided (see section
5.1).
_Adults aged 18 years and above_
TABLE 1:
HALOPERIDOL DECANOATE DOSE RECOMMENDATIONS FOR ADULTS AGED 18 YEARS
AND ABOVE
TRANSITION FROM ORAL HALOPERIDOL
A haloperidol decanoate dose of 10 to 15 times the previous daily dose
of oral haloperidol
is recommended.
Based on this conversion, the haloperidol decanoate dose will be 25
to150 mg for most
patients.
CONTINUATION OF TREATMENT
It is recommended to adjust the haloperidol decanoate dose by up to 50
mg every 4 weeks
(based on individual patient response) until an optimal therapeutic
effect is obtained.
The most effective dose is expected to range between 50 and 200 mg.
It is recommended to assess the individual benefit
-
risk when considering doses above
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
                                
                                Baca dokumen lengkapnya
                                
                            

Peringatan pencarian terkait dengan produk ini